These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3095 related items for PubMed ID: 32920628

  • 1. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH.
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [Abstract] [Full Text] [Related]

  • 2. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis.
    Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns LH.
    Neurobiol Aging; 2017 Jul; 55():99-114. PubMed ID: 28438486
    [Abstract] [Full Text] [Related]

  • 3. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A.
    Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, Burns LH.
    J Neurosci; 2012 Jul 18; 32(29):9773-84. PubMed ID: 22815492
    [Abstract] [Full Text] [Related]

  • 4. Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer's Disease.
    Wang HY, Cecon E, Dam J, Pei Z, Jockers R, Burns LH.
    Int J Mol Sci; 2023 Sep 11; 24(18):. PubMed ID: 37762230
    [Abstract] [Full Text] [Related]

  • 5. Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis.
    Wang HY, Trocmé-Thibierge C, Stucky A, Shah SM, Kvasic J, Khan A, Morain P, Guignot I, Bouguen E, Deschet K, Pueyo M, Mocaer E, Ousset PJ, Vellas B, Kiyasova V.
    Alzheimers Res Ther; 2017 Jul 27; 9(1):54. PubMed ID: 28750690
    [Abstract] [Full Text] [Related]

  • 6. Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development.
    Burns LH, Pei Z, Wang HY.
    Drug Dev Res; 2023 Sep 27; 84(6):1085-1095. PubMed ID: 37291958
    [Abstract] [Full Text] [Related]

  • 7. Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease.
    Burns LH, Wang HY.
    Neuroimmunol Neuroinflamm; 2017 Sep 27; 4(12):263-271. PubMed ID: 34295950
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.
    Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, Eichenlaub U, Dage JL, Chai X, Blennow K, Mattsson N, Hansson O.
    EMBO Mol Med; 2019 Dec 27; 11(12):e11170. PubMed ID: 31709776
    [Abstract] [Full Text] [Related]

  • 9. Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
    Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, Tolar M.
    Drugs; 2024 Jul 27; 84(7):825-839. PubMed ID: 38902572
    [Abstract] [Full Text] [Related]

  • 10. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40.
    Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Melo Dos Santos A, Epelbaum S, Lamari F, Genthon R, Dubois B, Floris R, Garaci F, Lista S, Alzheimer Precision Medicine Initiative (APMI).
    Alzheimers Dement; 2018 Apr 27; 14(4):492-501. PubMed ID: 29328927
    [Abstract] [Full Text] [Related]

  • 11. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
    de Oliveira FF, Miraldo MC, de Castro-Neto EF, de Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MDG.
    Aging Clin Exp Res; 2023 Aug 27; 35(8):1741-1752. PubMed ID: 37264166
    [Abstract] [Full Text] [Related]

  • 12. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H, Tesseur I, Pemberton D, Van Der Ark P, Timmers M, Slemmon R, Janssens L, Streffer J, Van Nueten L, Bottelbergs A, Rauramaa T, Koivisto AM, Herukka SK, Korhonen VE, Junkkari A, Hiltunen M, Engelborghs S, Blennow K, Zetterberg H, Kolb HC, Leinonen V.
    J Alzheimers Dis; 2021 Aug 27; 80(4):1629-1642. PubMed ID: 33720890
    [Abstract] [Full Text] [Related]

  • 13. Impairment of brain function in a mouse model of Alzheimer's disease during the pre-depositing phase: The role of α7 nicotinic acetylcholine receptors.
    Lykhmus O, Tzeng WY, Koval L, Uspenska K, Zirdum E, Kalashnyk O, Garaschuk O, Skok M.
    Biomed Pharmacother; 2024 Sep 27; 178():117255. PubMed ID: 39116785
    [Abstract] [Full Text] [Related]

  • 14. Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
    Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins ND, Sheardova K, Kesslak P, Shen L, Zhu X, Albayrak A, Paul J, Schaefer JF, Power A, Tolar M.
    Drugs; 2024 Jul 27; 84(7):811-823. PubMed ID: 38902571
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB.
    J Alzheimers Dis; 2016 Jul 27; 50(3):873-86. PubMed ID: 26836182
    [Abstract] [Full Text] [Related]

  • 16. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Milà-Alomà M, Salvadó G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, Sánchez-Benavides G, Arenaza-Urquijo EM, Crous-Bou M, González-de-Echávarri JM, Minguillon C, Fauria K, Simon M, Kollmorgen G, Zetterberg H, Blennow K, Suárez-Calvet M, Molinuevo JL, ALFA study.
    Alzheimers Dement; 2020 Oct 27; 16(10):1358-1371. PubMed ID: 32573951
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y, Nakamura T, Kawarabayashi T, Hirohata M, Narita S, Wakasaya Y, Kaito K, Ueda T, Harigaya Y, Shoji M.
    J Alzheimers Dis; 2019 Oct 27; 68(1):395-404. PubMed ID: 30814356
    [Abstract] [Full Text] [Related]

  • 18. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K, Kern S, Zettergren A, Börjesson-Hansson A, Zetterberg H, Skoog I, Blennow K.
    Transl Psychiatry; 2017 Jan 10; 7(1):e995. PubMed ID: 28072416
    [Abstract] [Full Text] [Related]

  • 19. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K.
    JAMA Neurol; 2019 Jul 01; 76(7):791-799. PubMed ID: 31009028
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, Gispert JD, Molinuevo JL, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage Clin; 2018 Jul 01; 19():190-201. PubMed ID: 30023169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 155.